You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Modernizing the Management of Heart Failure: Implementation Is Critical to Success

  • Authors: Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC; Gregg C. Fonarow, MD, FACC, FAHA, FHSA; Muthiah Vaduganathan, MD, MPH; Ewa A. Jankowska, MD, PhD, FESC
  • CPD Released: 9/13/2022
  • Valid for credit through: 9/13/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.75 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US cardiologists and primary care physicians.

The goal of this activity is that the learner will be better able to incorporate the latest data and evidence-based guidelines on HF therapy, including use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, into patient management.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data for early initiation of HF therapies
  • Have greater competence related to
    • The early initiation of HF therapies
    • Use of SGLT2 inhibitors for patients with HF across the spectrum of left ventricular ejection fraction


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Moderator

  • Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC

    Senior Consultant Cardiologist
    National Heart Center
    Professor of Medicine
    Duke National University
    Singapore, Singapore

    Disclosures

    Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC, has the following relevant financial relationships:
    Consultant or advisor for: Abbott; Actelion; Alleviant Medical; Allysta Pharma; Amgen; AnaCardio AB; Applied Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Scientific; Cytokinetics; Darma Inc.; EchoNous Inc; Impulse Dynamics; Ionis Pharmaceutical; Janssen Research & Development LLC; Merck; Novartis; Novo Nordisk; Prosciento Inc; Radcliffe Group Ltd.; Roche Diagnostics; Sanofi; Siemens Healthcare Diagnostics; Us2.ai
    Research funding from: Bayer; Roche Diagnostics
    Patent beneficiary of: Us2.ai US Patent No. 10,702, 247 Automated clinical workflow that recognizes and analyses 2-dimensional and Doppler echo images for cardiac measurements and the diagnosis, prediction and prognosis of heart disease
    Stock options from: Us2.ai
    Owns stock (privately owned) in: Us2.ai
    Other: Co-founder and Non-executive Director of Us2.ai

Faculty

  • Gregg C. Fonarow, MD, FACC, FAHA, FHSA

    Eliot Corday Professor of Cardiovascular Medicine and Science
    David Geffen UCLA School of Medicine
    Director, Ahmanson-UCLA Cardiomyopathy Center
    UCLA Medical Center
    Los Angeles, California, United States

    Disclosures

    Gregg C. Fonarow, MD, FACC, FAHA, FHSA, has the following relevant financial relationships:
    Consultant or advisor for: Abbott; Amgen; AstraZeneca; Cytokinetics; Egnite; Janssen; Medtronic; Merck; Novartis; Urovant

  • Muthiah Vaduganathan, MD, MPH

    Consultant Cardiologist
    Brigham and Women's Hospital, Division of Cardiovascular Medicine
    Faculty
    Harvard Medical School
    Boston, Massachusetts, United States

    Disclosures

    Muthiah Vaduganathan, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: American Regent; Amgen; AstraZeneca; Bayer AG; Baxter Healthcare; Boehringer Ingelheim; Cytokinetics; Lexicon Pharmaceuticals; Pharmacosmos; Relypsa; Roche Diagnostics; Sanofi
    Speaker or member of speakers bureau for: Novartis; Roche Diagnostics
    Research funding from: Amgen; AstraZeneca; Boehringer Ingelheim; Roche Diagnostics; Sanofi
    Other: Clinical Trial Committee for trials sponsored by Galmed; Novartis

  • Ewa A. Jankowska, MD, PhD, FESC

    Head, Department of Translational Cardiology and Clinical Registries
    Institute of Heart Diseases
    Wroclaw Medical University and University Hospital
    Wroclaw, Poland

    Disclosures

    Ewa A. Jankowska, MD, PhD, FESC, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Bayer; Boehringer Ingelheim; Cardiac Dimensions; Novartis; Respicardia; Servier; Vifor Pharma
    Speaker or member of speakers bureau for: Abbott; AstraZeneca; Bayer; Boehringer Ingelheim; Novartis; Pfizer; Servier; Takeda; Vifor Pharma

Editor

  • Anne M. Sendaydiego, PharmD

    Medical Education Director, WebMD Global, LLC 

    Disclosures

    Anne M. Sendaydiego, PharmD, has no relevant financial relationships.  

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance

    Disclosures

    Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Modernizing the Management of Heart Failure: Implementation Is Critical to Success

Authors: Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC; Gregg C. Fonarow, MD, FACC, FAHA, FHSA; Muthiah Vaduganathan, MD, MPH; Ewa A. Jankowska, MD, PhD, FESCFaculty and Disclosures

CPD Released: 9/13/2022

Valid for credit through: 9/13/2023

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Latest News in Heart Failure: Mandating a Modern Approach to Treatment

Dr Fonarow reviews the latest data and guidelines for HF treatment.
Gregg C. Fonarow, MD, FACC, FAHA, FHSA

Approach to HF Management and Role of LVEF

Dr Vaduganathan outlines how to use LVEF in HF management.
Muthiah Vaduganathan, MD, MPH

Overcoming Barriers to Optimal HF Care

Dr Jankowska outlines strategies to overcome barriers to HF care.
Ewa A. Jankowska, MD, PhD, FESC

What Changes Can I Make on Monday Morning?

Dr Lam uses several cases to discuss the management of patients with HF.
Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC
 

Educational Impact Challenge

The goal of this activity is that the learner will be better able to incorporate the latest data and evidence-based guidelines on HF therapy, including use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, into patient management.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.